報價延遲最少15分鐘:2025/01/21 18:57 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.791 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.38/-1.17
|
|
企業價值
27.54M
|
| 資產負債 |
|
每股賬面淨值
2.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.81M
|
|
每股收益
0.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:57 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detectionand/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |